Breaking News Instant updates and real-time market news.

BA

Boeing

$133.94

0.5566 (0.42%)

, AMGN

Amgen

$164.29

0.41 (0.25%)

13:02
10/14/16
10/14
13:02
10/14/16
13:02

Boeing names Amgen CEO Robert Bradway to board

The Boeing (BA) board of directors has elected Robert A. Bradway as a new member. Bradway is chairman and CEO of Amgen (AMGN).

BA

Boeing

$133.94

0.5566 (0.42%)

AMGN

Amgen

$164.29

0.41 (0.25%)

  • 26

    Oct

  • 05

    Nov

  • 06

    Nov

  • 19

    Jul

BA Boeing
$133.94

0.5566 (0.42%)

06/23/16
06/23/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Amazon.com (AMZN), eBay (EBAY), and Groupon (GRPN) initiated with a Buy at Maxim. 2. Boeing (BA) initiated with an Overweight at Morgan Stanley. 3. Wal-Mart (WMT) coverage assumed with a Buy at Nomura. 4. Textron (TXT) initiated with an Underweight at Morgan Stanley. 5. ANI Pharmaceuticals (ANIP) initiated with a Strong Buy at Raymond James. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/28/16
BERN
07/28/16
NO CHANGE
BERN
Boeing reported beat and raise results, says Bernstein
Bernstein analyst Douglas Harned says that Boeing reported higher than expected Q1 EPS and effectively raised its EPS guidance by $1..18 per share. Harned says that the company's 787 unit margins appear to be running ahead of expectations. He expects the company to generate strong cash flow growth going forward. Harned keeps a $176 price target and Outperform rating on the stock.
10/05/16
BARD
10/05/16
INITIATION
BARD
Outperform
Boeing initiated with an Outperform at Baird
Baird analyst Peter.Arment initiated Boeing with an Outperform and a $161 price target.
10/06/16
10/06/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Boeing (BA) initiated with an Outperform at Baird. 2. AMC Networks (AMCX) initiated with an Outperform at FBN Securities. 3. CVS Health (CVS) initiated with a Buy at UBS. 4. L-3 Communications (LLL) initiated with an Outperform at Baird. 5. Raytheon (RTN) initiated with an Outperform at Baird. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
AMGN Amgen
$164.29

0.41 (0.25%)

09/01/16
09/01/16
NO CHANGE

Amgen's sBLA for Blincyto approved by FDA
Amgen's supplemental Biologics License Application for Blincyto has been approved by the FDA to include new data supporting the treatment of pediatric patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia. This indication is approved under accelerated approval, and continued approval may be contingent upon verification of clinical benefit in subsequent trials. The approval is based on results from the Phase 1/2 '205, an open-label, multicenter, single-arm trial, which evaluated the efficacy and safety of BLINCYTO in pediatric patients with relapsed or refractory B-cell precursor ALL. Blincyto was granted breakthrough therapy, priority review and orphan drug designations by FDA, and is now approved in the U.S. for the treatment of Ph- relapsed or refractory B-cell precursor ALL. In November 2015, BLINCYTO was granted conditional marketing authorization in the European Union for the treatment of adults with Ph- relapsed or refractory B-cell precursor ALL.
09/27/16
GSCO
09/27/16
NO CHANGE
Target $206
GSCO
Conviction Buy
Goldman surprised by Amgen's Kyprolis outcome in first-line multiple myeloma
Last night, Amgen announced Phase 3 Kypolis CLARION study did not meet the primary endpoint in first-line multiple myeloma. Goldman analyst Terence Flynn was surprised by this outcome given the prior positive superiority data for Kyprolis versus Velcade in the Phase III ENDEAVOR trial. Flynn sees risk to his Kyprolis $1B sales estimate in a first-line setting, but awaits for additional details from the call and further information regarding another ongoing Phase III trial. He expects Amgen shares to be weak on the news but said the company has additional drivers beyond Kyprolis including Repatha for high cholesterol and Erenumab for migraine with additional data expected in 2H 2016 and Q1 2017. Flynn remains Conviction Buy rated on Amgen and maintains his $206 price target.
09/27/16
PIPR
09/27/16
NO CHANGE
PIPR
Overweight
Amgen's Kyprolis in good shape despite trial miss, says Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says Amgen's Kyprolis is still likely to be viewed as a "potent backbone, with the right drugs" after a Phase 3 study in front-line myeloma failed to reach its primary endpoint. The analyst believes the impact of the failed trial on Kyprolis use will be limited and he reiterates an Overweight rating on Amgen.
09/29/16
PIPR
09/29/16
NO CHANGE
Target $10
PIPR
Overweight
Arrowhead price target raised to $10 from $8 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Arrowhead Pharmaceuticals (ARWR) to $10 after the company licensed two preclinical cardiovascular RNAi drugs with Amgen (AMGN). Amgen is the "ideal partner" and Arrowhead's balance sheet is now "meaningfully" strengthened, Tenthoff tells investors in a research note. He reiterates an Overweight rating on Arrowhead.

TODAY'S FREE FLY STORIES

CTMX

CytomX Therapeutics

$14.45

-0.45 (-3.02%)

08:15
06/28/17
06/28
08:15
06/28/17
08:15
Hot Stocks
CytomX Therapeutics treats first patient in Phase 1/2 PROCLAIM-CX-2009 trial »

CytomX Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

08:15
06/28/17
06/28
08:15
06/28/17
08:15
General news
Energy Action: NYMEX »

Energy Action: NYMEX…

08:15
06/28/17
06/28
08:15
06/28/17
08:15
General news
International Trade in Goods Balance to be reported at 08:30 »

May International Trade…

LNCE

Snyder's-Lance

$34.88

-1.27 (-3.51%)

08:14
06/28/17
06/28
08:14
06/28/17
08:14
Hot Stocks
Snyder's-Lance appoints Brian Driscoll as CEO »

Snyder's-Lance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MON

Monsanto

$117.25

-0.55 (-0.47%)

08:14
06/28/17
06/28
08:14
06/28/17
08:14
Earnings
Monsanto sees FY17 ongoing EPS $4.50-$4.90, consenus $4.89 »

The company confirms EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

MON

Monsanto

$117.25

-0.55 (-0.47%)

, BAYRY

Bayer

$137.59

0.89 (0.65%)

08:14
06/28/17
06/28
08:14
06/28/17
08:14
Earnings
Monsanto reports Q3 ongoing EPS $1.93, consensus $1.76 »

Reports Q3 revenue…

MON

Monsanto

$117.25

-0.55 (-0.47%)

BAYRY

Bayer

$137.59

0.89 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

TYG

Tortoise Energy

$29.13

-0.14 (-0.48%)

08:13
06/28/17
06/28
08:13
06/28/17
08:13
Upgrade
Tortoise Energy rating change  »

Tortoise Energy upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GBT

Global Blood Therapeutics

$27.50

-0.4 (-1.43%)

08:12
06/28/17
06/28
08:12
06/28/17
08:12
Hot Stocks
Global Blood Therapeutics receives EMA PRIME designation for GBT440 »

Global Blood Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNF

UniFirst

$139.05

-1.25 (-0.89%)

08:12
06/28/17
06/28
08:12
06/28/17
08:12
Earnings
UniFirst sees FY17 EPS $4.85-$5.00, consensus $5.01 »

Sees FY17 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

UNF

UniFirst

$139.05

-1.25 (-0.89%)

08:11
06/28/17
06/28
08:11
06/28/17
08:11
Earnings
UniFirst reports Q3 adj. EPS $1.36, consensus $1.34 »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

MNRO

Monro Muffler

$45.15

-0.8 (-1.74%)

08:10
06/28/17
06/28
08:10
06/28/17
08:10
Hot Stocks
Monro Muffler appoints Ponton to succeed Van Heel as CEO »

Monro Muffler Brake…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUVA

NuVasive

$75.54

-1.15 (-1.50%)

08:08
06/28/17
06/28
08:08
06/28/17
08:08
Recommendations
NuVasive analyst commentary  »

NuVasive price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 15

    Aug

CA

CA Technologies

$34.62

-0.19 (-0.55%)

08:08
06/28/17
06/28
08:08
06/28/17
08:08
Recommendations
CA Technologies analyst commentary  »

Potential CA Technologies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XPO

XPO Logistics

$60.84

-0.32 (-0.52%)

08:06
06/28/17
06/28
08:06
06/28/17
08:06
Initiation
XPO Logistics initiated  »

XPO Logistics initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jul

CBI

CB&I

$20.03

5.63 (39.10%)

08:04
06/28/17
06/28
08:04
06/28/17
08:04
Hot Stocks
CB&I awarded contract by Shurtan Gas Chemical Complex »

CB&I announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LMNX

Luminex

$20.92

-0.3 (-1.41%)

08:04
06/28/17
06/28
08:04
06/28/17
08:04
Hot Stocks
Luminex receives CE-IVD mark for ARIES Norovirus Assay »

Luminex announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jul

NVIV

InVivo Therapeutics

$2.75

0.2 (7.84%)

08:04
06/28/17
06/28
08:04
06/28/17
08:04
Hot Stocks
InVivo Therapeutics reports two patients in study improve in INSPIRE assessments »

InVivo Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

MSA

MSA Safety

$79.73

0.44 (0.55%)

08:03
06/28/17
06/28
08:03
06/28/17
08:03
Hot Stocks
MSA Safety to acquire Globe Holding Company for $215M in cash »

MSA Safety announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCA

HCA Holdings

$86.01

-0.61 (-0.70%)

07:59
06/28/17
06/28
07:59
06/28/17
07:59
Initiation
HCA Holdings initiated  »

HCA Holdings initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STT

State Street

$87.90

0.08 (0.09%)

07:59
06/28/17
06/28
07:59
06/28/17
07:59
Upgrade
State Street rating change  »

State Street upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

OLN

Olin Corp.

$29.31

0.29 (1.00%)

07:58
06/28/17
06/28
07:58
06/28/17
07:58
Recommendations
Olin Corp. analyst commentary  »

Cowen calls Olin Corp. a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DSKE

Daseke

$10.40

0.09 (0.87%)

07:57
06/28/17
06/28
07:57
06/28/17
07:57
Recommendations
Daseke analyst commentary  »

Daseke revenue synergies…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TRU

TransUnion

$43.52

-0.78 (-1.76%)

07:57
06/28/17
06/28
07:57
06/28/17
07:57
Recommendations
TransUnion analyst commentary  »

TransUnion guidance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

COST

Costco

$159.26

-0.94 (-0.59%)

, AMZN

Amazon.com

$976.78

-17.2 (-1.73%)

07:56
06/28/17
06/28
07:56
06/28/17
07:56
Recommendations
Costco, Amazon.com analyst commentary  »

Costco weakness a buying…

COST

Costco

$159.26

-0.94 (-0.59%)

AMZN

Amazon.com

$976.78

-17.2 (-1.73%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 23

    Aug

PYPL

PayPal

$52.73

-1.01 (-1.88%)

07:55
06/28/17
06/28
07:55
06/28/17
07:55
Recommendations
PayPal analyst commentary  »

PayPal shares could…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jun

  • 29

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.